MedPath

Gradual Vs. Rapid Buprenorphine Detoxification - 2

Phase 1
Completed
Conditions
Opioid-Related Disorders
Registration Number
NCT00000220
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Brief Summary

The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Drug use
Retention
Observed withdrawal rating
Opioid agonist rating
Opioid antagonist rating
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Treatment Research Center

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath